Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (NASDAQ: SLP) is a leading developer of modeling and simulation software and consulting services that support drug discovery, development research, and regulatory submissions. The company collaborates with pharmaceutical organizations to implement a data-driven, strategic modeling methodology that begins in early discovery stages, extends through preclinical and clinical development, and continues into clinical trials and post-approval phases.
Simulations Plus, through its subsidiaries Cognigen Corporation and DILIsym Services, offers a suite of top-ranked, user-friendly software solutions. These include GastroPlus™, ADMET Predictor™, KIWI™, DILIsym®, NAFLDsym®, PKPlus™, and more. These tools bridge data mining and compound library screening with QSAR models and PBPK/TK modeling and simulation in both animals and humans. The company's quantitative systems pharmacology approaches are widely recognized and licensed by regulatory agencies globally.
In addition to software development, Simulations Plus provides consulting and contract research services to the pharmaceutical industry. The company’s operations are divided into two primary segments: software and services. The software segment generates the majority of the company’s revenue.
Over the past 20 years, Simulations Plus has consistently partnered with clients to reduce costs and accelerate research timelines. The company’s innovative technology and methodologies have earned it a reputation as a reliable partner in the pharmaceutical industry.
Latest News: Simulations Plus continues to make headlines with its innovative solutions and strategic partnerships. Stay updated with the latest developments and achievements of Simulations Plus on our news section.
Simulations Plus (NASDAQ: SLP) announced record attendance for the 2022 MIDD+ Scientific Conference held on February 16-17, attracting participants from 57 countries. The event focused on advancing model-informed drug development with sessions covering all drug development stages. Keynote speaker Rajanikanth Madabushi from the FDA emphasized a holistic approach. Presentations included regulatory perspectives from global agencies. The conference highlights the company's leadership in biosimulation and its role in the pharmaceutical industry.
Simulations Plus (NASDAQ: SLP) announced it will report its financial results for the second quarter of fiscal year 2022 on April 6, 2022, after market close. The announcement includes a conference call scheduled for 5:00 PM ET on the same day, where stakeholders can join via registration link or phone. The company provides advanced biosimulation software and consulting services for drug discovery, and has been in operation for 25 years, serving clients globally.
Simulations Plus (NASDAQ: SLP) has launched MembranePlus™ 3.0, enhancing in vitro-in vivo extrapolation (IVIVE) for transdermal product analysis. Key features include new models for in vitro penetration and release tests, expanded membrane transport parameters, and improved simulation performance. The update aims to provide insights for formulation strategies, reducing the need for animal testing. Senior Scientist Dr. Jessica Spires noted the product's integration with GastroPlus® to benefit researchers in predicting topical administration outcomes.
Simulations Plus (Nasdaq: SLP) announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference, occurring virtually on March 15-16, 2022. CEO Shawn O’Connor will present on March 15 at 4:00 p.m. ET and will also host one-on-one meetings. Interested parties can access the live event or request meetings via their Oppenheimer representatives. The presentation slides will be available afterwards on the company’s Investors page.
Simulations Plus, serving clients for 25 years, specializes in modeling and simulation software for pharmaceutical development and research.
Simulations Plus, a leader in biosimulation software, will present at the Raymond James 43rd Annual Institutional Investors Conference from March 6-9, 2022, in Orlando, Florida. CEO Shawn O’Connor is scheduled to present on March 9 at 10:25 a.m. ET and will conduct one-on-one meetings. Attendance is by invitation only. The presentation will be available on the Simulations Plus Investors page. This conference is a key event for engaging with institutional investors and showcasing advancements in pharmaceutical modeling and simulation.
Simulations Plus (Nasdaq: SLP), a key player in biosimulation software for pharmaceuticals, announced participation in BTIG's MedTech, Digital Health, Life Science and Diagnostic Tools Conference from February 15-17, 2022. CEO Shawn O'Connor will present on February 15 at 3:30 p.m. ET and will be available for one-on-one meetings. Interested parties can view the slide presentation on the investors page post-presentation. For more details on the event, visit BTIG's website.
Simulations Plus (NASDAQ: SLP) announced a new collaboration with a large pharmaceutical company to enhance its GastroPlus® ACAT™ model for better understanding of drug disposition in the gastrointestinal tract. The partnership aims to improve functionalities related to local gut delivery and bolster data handling for drug evaluation. This initiative reflects the company's commitment to advancing drug development processes and solidifying its position in biosimulation.
Simulations Plus has announced a new funded collaboration with a major animal health company to enhance its GastroPlus platform. This partnership aims to validate existing animal physiologically based pharmacokinetic (PBPK) models and introduce new species to the platform. The collaboration will bolster veterinary medicine and food production research, promoting animal welfare and public health. Leaders from Simulations Plus emphasized the significance of this expansion into animal health markets, aiming to develop innovative modeling tools.
Simulations Plus, Inc. (NASDAQ: SLP) announced that CEO Shawn O’Connor will present at the Sidoti Winter Small Cap Investor Conference on January 19–20, 2022. O’Connor's presentation is scheduled for January 19, 2022, at 4:00 p.m. ET. Investors can access a live webcast through the Sidoti website. Simulations Plus, a leader in biosimulation, supports drug discovery and development across the globe.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
What does Simulations Plus, Inc. do?
What are the main products of Simulations Plus?
How does Simulations Plus support drug development?
Who uses Simulations Plus technology?
What are the primary segments of Simulations Plus’ operations?
Which subsidiaries are part of Simulations Plus?
How long has Simulations Plus been in operation?
Where is Simulations Plus headquartered?
Does Simulations Plus offer consulting services?
How can I stay updated on Simulations Plus’ latest news?
